# Different Doses of Naronapride vs. Placebo in Gastroparesis

> **NCT05621811** · PHASE2 · COMPLETED · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 328 (actual)

## Conditions studied

- Gastroparesis

## Interventions

- **DRUG:** Naronapride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05621811
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-03
- **Primary completion:** 2025-08-12
- **Final completion:** 2025-09-04
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05621811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05621811, "Different Doses of Naronapride vs. Placebo in Gastroparesis". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT05621811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*